MELBOURNE, Australia and SAN FRANCISCO, June 29, 2020 /PRNewswire/ — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for…

This post was originally published on this site